Your browser doesn't support javascript.
loading
Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.
Weber, Felix; Bohrmann, Bernd; Niewoehner, Jens; Fischer, Jens A A; Rueger, Petra; Tiefenthaler, Georg; Moelleken, Joerg; Bujotzek, Alexander; Brady, Kevin; Singer, Thomas; Ebeling, Martin; Iglesias, Antonio; Freskgård, Per-Ola.
  • Weber F; Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Bohrmann B; Pharma Research and Early Development (pRED), Neurodegeneration and Regeneration, Roche Innovation Center, Basel, Switzerland.
  • Niewoehner J; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Fischer JAA; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Rueger P; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Tiefenthaler G; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Moelleken J; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Bujotzek A; Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.
  • Brady K; Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Singer T; Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Ebeling M; Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Iglesias A; Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland. Electronic address: antonio.iglesias@roche.com.
  • Freskgård PO; Pharma Research and Early Development (pRED), Neurodegeneration and Regeneration, Roche Innovation Center, Basel, Switzerland. Electronic address: per-ola.freskgard@roche.com.
Cell Rep ; 22(1): 149-162, 2018 01 02.
Article en En | MEDLINE | ID: mdl-29298417
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Barrera Hematoencefálica / Sistemas de Liberación de Medicamentos / Receptores de IgG / Enfermedad de Alzheimer / Anticuerpos Monoclonales Límite: Animals / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Barrera Hematoencefálica / Sistemas de Liberación de Medicamentos / Receptores de IgG / Enfermedad de Alzheimer / Anticuerpos Monoclonales Límite: Animals / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article